eHealth, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 28, 2025, discloses significant changes in executive leadership for eHealth, Inc. (Nasdaq: EHTH). The filing details the resignation of the current Chief Executive Officer (CEO) and the immediate appointment of a successor, effective following a Board meeting scheduled for September 18, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- CEO Resignation: Fran Soistman has resigned as CEO and from all other roles except Board membership. His resignation is effective immediately prior to the Board meeting on September 18, 2025. He will serve as an executive advisor until December 31, 2025.
- CEO Appointment: The Board appointed Derrick Duke as the new CEO, effective immediately following Mr. Soistman's resignation. Mr. Duke will join the company on August 4, 2025, to begin the transition.
- Executive Background: Mr. Duke previously served as CEO of Magellan Health, Inc. (since May 2022) and held various executive roles at HealthMarkets, Inc.
Compensation, Guidance, and Risks
The filing outlines the compensatory arrangements for the new CEO, Derrick Duke, which include:
- Base Salary: $700,000 annually.
- Target Incentive: 120% of annual base salary.
- Signing Bonus: $600,000, subject to repayment if terminated for cause or resignation without good reason within one year.
- Equity Awards:
- 300,000 time-based Restricted Stock Units (RSUs) vesting in three equal annual installments.
- 300,000 performance-based RSUs subject to a three-year performance period.
- Severance Provisions:
- Qualifying Termination (Without Cause/Good Reason): 24 months of base salary, pro-rated bonus, 18 months of COBRA benefits, and accelerated vesting of equity awards.
- Change in Control: 24 months of base salary, 200% of target annual bonus, and full vesting of outstanding equity awards.
Management Commentary: The Board concluded its search for a successor to facilitate a transition period. No specific financial guidance or outlook was provided in this filing.
Investor Verification Checklist
- Verify the exact effective date of Derrick Duke's CEO appointment relative to the September 18, 2025 Board meeting.
- Review the attached Exhibits 10.1 (Offer Letter) and 10.2 (Severance Agreement) for specific definitions of "cause," "good reason," and "change in control."
- Monitor the transition period to ensure Fran Soistman's role as executive advisor does not conflict with the new CEO's authority.
- Check subsequent filings for the formal approval of Mr. Duke's appointment to the Board of Directors.